Grace Therapeutics develops and commercializes novel drug delivery formulations for rare and orphan diseases by applying proprietary technologies to approved pharmaceutical compounds to improve efficacy, safety, patient convenience, and compliance. The company's pipeline includes three clinical-stage candidates with FDA orphan drug designations, leveraging a Section 505(b)(2) regulatory pathway that may offer faster approval timelines by building on the established safety profiles of existing drugs. Grace generates value through a combination of patent protection, orphan drug exclusivity, and planned direct commercialization of approved products, particularly through hospital-based sales models, while remaining open to strategic partnerships and licensing opportunities for non-core assets.